Yesterday, Celgene Corporation (CELG) announced that its cancer drug Revlimid met the main goal in a randomized, double-blind, multi-center late-stage study (IFM 2005 02). The study, sponsored by the Intergroupe Francophone du Myelome and University Hospital of Toulouse, evaluated Revlimid compared to placebo in patients suffering from multiple myeloma (MM) who had undergone an autologous [...] (CELG) Celgene Corporation Announces Good News for Cancer Drug Study